Pharmacokinetic analysis revealed a clear advantage: CLONAPURE® delivered roughly twice the plasma creatine bioavailability of CrM, highlighting its superior efficiency in energy production.
Safety
Studies confirmed identical cell viability to creatine monohydrate across all tested concentrations, with no evidence of cytotoxicity. In human trials, no adverse effects were reported, and Clonapure® was well tolerated, confirming its suitability for long-term and daily use.
References: 1. Lapena-Luzon, T., Hernandez-Bueno, A., Tomas Cobos, L., Moreno-Puente, P., Garcia-Benlloch, S., et al. (2025). Evaluation of the Effect of Clonapure® Versus Creatine Monohydrate on ATP Levels in a C2C12 Muscle Cell Line. American Journal of Sports Science, 13(2), 50-56. 2. fhn Corp. (2024). Dossier: Effect of creatine monohydrate and Clonapure® on plasma creatine concentration [Pilot clinical study]